the preclinical data in crizotinib means little at this point considering the remarkable effects it has had in humans. do you really think that pfizer doesnt know which target its hitting at this point, lol? clearly, all the preclinical and clinical evidence points directly to a ALK positive patient having a dramatic effect on the drug.
im not sure i am really following your post.
the entire scientific community doesnt have it wrong.
but it I'm not convinced that a drug that targets only ALK will be efficacious in the clinic
Based on my understanding of the pathway, if it's a tumor caused by an ALK rearrangement, then inhibiting ALK is all you need. Along the same lines as BCR/ABL in CML.
Pona of course currently has a much higher risk-adjusted NPV than does '113, but '113 in my view has greater ultimate potential.
Market Data 
Markets 
AI
